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Introduction: In patients with systemic sclerosis (SSc), digital ischemia results from an occlusive microvasculopathy
that may not respond adequately to conventional vasodilators. Endothelin receptor antagonists can potentially
modify the fibroproliferative vascular remodeling in SSc, and hence their use may be justified in the management of
digital ischemia. The objective of this clinical trial was to evaluate the effect of ambrisentan, a selective endothelin type
A receptor antagonist, on microvascular blood flow in patients with limited systemic sclerosis (SSc) using laser Doppler
perfusion imaging (LDPI).
Methods: In this randomized, double-blind, placebo controlled study we enrolled 20 patients with limited SSc. Fifteen
patients received ambrisentan 5 mg daily for one month and then 10 mg daily for two months, and five received a
placebo. There were three visits: weeks 0 (baseline), one and 12. Three patient-oriented questionnaires were completed
at each visit: Scleroderma-Health Assessment Questionnaire (S-HAQ), Raynaud Condition Score (RCS), and Pain-Visual
Analog Scale (P-VAS). At each visit, LDPI was used to obtain three blood flow readings involving regions of interest in
second to fifth fingers of the non-dominant hand at room temperature (25°C) and after cooling (10°C) for two minutes.
Results: There were 16 females (80%); mean age was 50 years. None of the differences in blood flow (as measured
by LDPI) were significant both at baseline and after cooling. However, patients in the ambrisentan group showed
significant improvement in the patient-oriented outcomes: RCS (P = 0.001) and S-HAQ score (P = 0.005).
Conclusions: This pilot study did not show evidence of significant increase in digital blood flow over time; however,
there was an improvement in RCS and S-HAQ score. We conclude that continuous use of ambrisentan for three months
does not seem to significantly improve digital blood flow in SSc patients.
Trial registration: Clinicaltrials.gov NCT01072669. Registered 19 February 2010.Introduction
Raynaud phenomenon (RP) affects 90% to 95% of pa-
tients with systemic sclerosis (scleroderma, SSc), result-
ing in digital ulcers in approximately 30% of patients
annually [1-3]. The proliferative microvasculopathy lead-
ing to digital ischemia not only results in hypoxemic* Correspondence: chattes@ccf.org
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stated.tissue damage, but it also initiates fibroblast activation
and promotes tissue fibrosis.
Endothelial injury is thought to precede loss of normal
vasodilator response to nitric oxide and prostacyclin, lead-
ing to abnormal responses to vasoconstrictive mediators
including endothelin-1 (ET-1) and catecholamines [4].
Serum ET-1 level is increased in SSc patients [5,6] making
it a rational therapeutic target in this disease [7].
The use of endothelin receptor antagonists may be
justified in SSc patients with digital ischemia refractory tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Assessed for eligibility (n = 21)
Excluded: declined
to participate (n = 1)
Allocated to ambrisentan (n = 15)
Completed course of ambrisentan 
(n = 13)
Did not complete course of
ambrisentan (n = 2) 
[1 stopped drug after 4 weeks but 
came for 12-week analysis; 1 
discontinued drug after 4 weeks 
and did not follow-up]
Allocated to placebo and 
completed course (n = 5)
Randomized (n = 20)
Figure 1 Trial profile.
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dilator properties, these drugs also have favorable effects
on fibro-proliferative vascular remodeling in the long term.
It has been shown that small doses of bosentan, a dual
endothelin receptor antagonist, improve endothelial func-
tion in SSc patients without altering hemodynamic param-
eters [8]. This would support a direct, reversible effect of
endothelin in SSc associated vasculopathy.
Assessment and documentation of the extent and se-
verity of digital microvascular involvement in SSc have
been challenging, and have been traditionally based on
clinical impressions [9]. In addition, interpretation of
therapeutic responses in RP has also typically been based
on highly subjective patient-reported responses. Lately,
laser Doppler perfusion imaging (LDPI) has gained ac-
ceptance as an emerging technology that allows object-
ive measurement of cutaneous blood flow in RP. Prior
studies including our own validated that LDPI reliably
evaluates digital microvascular flow in SSc [10-18].
The Doppler principle has been utilized by LDPI tech-
nology to calculate skin perfusion, since the magnitude
and frequency distribution of the Doppler shifted light
are directly related to the number and velocity of mov-
ing blood cells. LDPI involves perfusion mapping of
areas, rather than examination of blood flow at a single
point as with laser Doppler flowmetry [19]. Cutaneous
perfusion is unaffected, as there is no physical contact
with skin, and dyes or tracer elements are not required.
Measuring blood flow in adjacent points within an image
and performing averaging techniques overcomes the
problem with point to point cutaneous blood flow het-
erogeneity, and provides clinically meaningful evaluation
of perfusion. It also allows more precise statistical as-
sessment of change in blood flow with pharmacologic
intervention.
ET-1 antagonists are effective in pulmonary arterial
hypertension (PAH) in SSc and, hence, received regula-
tory approval for this indication. In addition, bosentan
has been shown to decrease the occurrence of new
digital ulcers in patients with SSc [2,9].
Ambrisentan selectively blocks the vasoconstrictive ef-
fect of ETA receptor stimulation, leaving the vasodilatory
effect of ETB receptor stimulation unopposed. It has
demonstrated a significant improvement in exercise cap-
acity (six-minute walk) along with clinical improvement
in patients with idiopathic and SSc-associated PAH with
World Health Organization (WHO) functional class II
and III symptoms [20]. A small prospective open-label
study (20 patients) demonstrated that ambrisentan may
also be useful in reducing ulcer burden and healing is-
chemic digital ulcers in SSc [21]. These studies led us to
hypothesize that ambrisentan increases digital micro-
vascular flow (as measured by LDPI) in patients with RP
secondary to SSc.Methods
Study design
We conducted a randomized, double-blind, placebo con-
trolled trial (ClinicalTrials.gov identifier: NCT01072669)
to evaluate the effect of ambrisentan on digital micro-
vascular blood flow in patients with limited SSc over a
three-month period. Subjects were recruited from the
Cleveland Clinic SSc database. Twenty patients were
randomized to ambrisentan or placebo in a 3:1 ratio and
each patient was treated for a total period of three
months (Figure 1). The study was approved by the insti-
tutional review board of the Cleveland Clinic, Cleveland,
Ohio, U.S.A.
Subjects
Subjects had limited SSc with disease duration <8 years
and satisfied the American College of Rheumatology
1980 criteria for diagnosis [1,22]. Informed consents
were obtained from all patients prior to participation in
the study. Only patients with limited SSc were included,
in order to have a fairly homogeneous group of patients
with chronic digital ischemia, who are less likely to drop
out during the course of the study because of major in-
ternal organ complications of SSc. RP was defined as
episodic, bilateral, digital color changes (at least two out
of three possible phases: pallor, cyanosis, rubor), pro-
voked by cold exposure or by emotional stress. Subjects
were ≥18 years of age and were able to give informed
consent. Patients with any of the following conditions
were excluded: (1) active digital ulcers or prior history of
digital ulcers with resultant scarring or significant pitting
of digits in the regions of interest (ROI), (2) pregnancy
(ambrisentan is pregnancy category X) or inability to
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during the study, (3) moderate to severe hepatic dys-
function, (4) hemoglobin <10% below the lower limit of
normal, (5) advanced cardiopulmonary disease, (6) in-
ability to discontinue conventional vasodilator treat-
ment for RP at least one week prior to study initiation,
(7) PAH, (8) concomitant use of medications that are
known to interact with ambrisentan [23] and (9) current
tobacco use.
Treatment and evaluation protocol
Patients underwent a physical examination at baseline
along with measurement of hemoglobin level, liver func-
tion (alanine aminotransferase (ALT), aspartate amino-
transferase (AST) and bilirubin), and urine or serum
pregnancy test [20,23]. Women of reproductive age had
to use two reliable forms of contraception along with
appropriate counseling, unless they had tubal ligation or
an intrauterine device (IUD) [23]. Subjects had to ab-
stain from caffeine and other vasoactive agents, at least
two days prior to randomization and throughout the
study period. Patients also stopped concurrent medica-
tions for RP one week prior to initiation of study drug/
placebo and had to stay off these medications throughout
the study period. Storage, dispensing and randomization of
ambrisentan and the matching placebo were conducted
under the supervision of our institutional research pharmacy.
Investigators and patients were blinded to the treatment.
After baseline evaluation, patients were randomized to
ambrisentan or placebo and underwent three visits at
weeks 0, 1 and 12. Subjects received ambrisentan 5 mg
orally daily or identical placebo for the first four weeks
and then were up-titrated to ambrisentan 10 mg daily or
placebo for the rest of the study. Adherence to treatment
was assessed by pill counting at each follow-up visit.
The non-dominant hand was used for scanning unless
precluded by digital ulcers, skin infections, injury, surgi-
cal scars, or amputations. The index, middle, ring and
little fingers were designated as regions 1, 2, 3 and 4,
respectively. The region of worst perfusion was also
selected for each patient and evaluated over the study
period. All study measurements were taken in a quiet
room, with subjects seated comfortably with their non-
dominant forearm resting on a table at heart level.
At each visit, three baseline blood flow readings were
recorded at room temperature (25°C), and three after
cooling of the fingers (10°C for two minutes, with the
help of a cooling flask). The cooling flask was a 1,000 ml
spherical glass flask that contained ice and water, the
surface temperature of which was maintained at 10°C
with a thermometer and a stirrer. Patients placed their
hand around the flask for two minutes to achieve cool-
ing of the fingers to 10°C, before each of the three obser-
vations at cold temperature. Regions of interest (ROI)over the dorsum of the second to fifth fingers distal to the
distal inter-phalangeal joints were selected, and the mean of
each of these three sets of readings was obtained. At each
visit, patients also completed three questionnaires: the
Scleroderma-Health Assessment Questionnaire (S-HAQ)
[24], Raynaud Condition Score (RCS) [25], and Pain-Visual
Analogue Scale (P-VAS) [26] (Additional files 1, 2 and 3).
Safety monitoring
Patients were carefully monitored for adverse events. Due
to the hepatotoxic potential of ambrisentan, monthly liver
function tests were performed during the study period.
Study treatment was to be withheld if hepatic transami-
nases were elevated to >3 times the upper limit of normal
(ULN) or bilirubin to >2 times the ULN; if levels did not
return to normal, treatment was to be permanently dis-
continued. Hemoglobin levels were also checked at one
and three months. For female patients, a serum or urine
pregnancy test was checked once a month, unless they
were post-menopausal and/or had a history of IUD place-
ment, sterilization or hysterectomy. Counseling for
women of childbearing potential (n = 3) regarding consist-
ent use of two reliable forms of contraception was rein-
forced at each visit. These women were advised against
pregnancy for at least one month after completion of the
study.
Laser Doppler perfusion imaging (LDPI) technology
The Perimed PeriScan PIM II Laser Doppler Perfusion
Imager uses a low power laser beam operating at 670
nm wavelength with a maximum depth of 0.6 mm and
average depth of 0.3 mm [27]. The imager targets the
Doppler signal to the skin surface. Backscattered light
from the skin surface is registered by a photo detector in
the scanner head that lies about 30 cm above the tissue
surface. The reading is then reported to an integrated
software system (LDPIwin®) that processes the signal
and performs statistical calculations [11,19]. Perfusion
signals appear as two-dimensional color coded images
(flow-maps of the spatial distribution of tissue perfusion)
with a scale ranging from dark blue (lowest value) to red
(highest value). Blood flow measurement by LDPI is
commonly referred to as ‘flux’ and expressed in perfu-
sion units (pU) [27].
Statistical methods
Sample size analyses
Sample size calculations were performed based on data
from our previous pilot study on SSc patients [11],
where mean perfusion under normal conditions for SSc
patients was 1.05 pU, with a standard deviation (SD) of
0.40 pU. With a 3:1 randomization scheme and using a
SD of 0.40, with 20 patients, it was calculated that there
would be at least 80% power to detect differences in the
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units and 0.45 units, under the assumptions of moderate
(r = 0.50) and strong (r = 0.75) correlation between time
points, respectively. These power calculations were per-
formed using SAS software (version 9.1, Cary, NC, USA).Randomization
A blocked randomization scheme was used since sea-
sonal differences may exist in symptom severity. The
randomization list was provided by the Quantitative
Health Sciences Department of our institution. Analyses
were performed using the intention-to-treat principle.
Clinical and demographic factors including age, race,
gender, and disease duration were collected for each
subject, and summarized using means and standard de-
viations for continuous measures and frequencies and
percentages for categorical factors. To assess differences
in perfusion levels over time, the mean perfusion across
all four finger ROIs was calculated for each scan. ROI
perfusion levels were calculated using unweighted, vari-
ance weighted, and site weighted means. Results were
very similar, so for brevity, only unweighted means are
reported here.
Repeated measure analysis of variance models were
then fitted using a compound symmetry correlation
structure. These models used all three time points and
allowed evaluation of overall differences across time as
well as paired differences between time points. In each
model, the survey or ROI response was used as the re-
sponse, while time, treatment and their interaction were
used as predictors. Models for ROI were fitted separately
for normal and cold conditions because the correlation
pattern differed across conditions. Statistical modeling
was performed using the Mixed Procedure with SAS
software (version 9.1, Cary, NC, USA). All hypothesis
tests used a 0.05 significance level. No corrections for
multiple comparisons were performed.
Study data were collected and managed using REDCap
electronic data capture tools [28]. REDCap (Research
Electronic Data Capture) is a secure, web-based applica-
tion designed to support data capture for research stud-
ies, providing an intuitive interface for validated data
entry and automated export procedures for seamless
data downloads to common statistical packages.Outcomes
We expected blood flow changes at one week to reflect
treatment effect (if any) related to vasodilatation and at
three months to the anti-fibro-proliferative effects of
ambrisentan. Therefore, the primary outcome measures
were the mean change of blood flow at one week and at
twelve weeks of treatment. Secondary outcome measures
included changes in S-HAQ scores, RCS, P-VAS scores,progression or regression of digital ulcers outside the
ROI, and safety and tolerability.
Results
Out of 21 patients screened, 20 were included in the
study; 15 were assigned to ambrisentan and 5 to placebo
(Figure 1). The two groups were well matched with re-
spect to demographic features, baseline disease charac-
teristics and prior therapy (Table 1). Sixteen patients
were women (80%) and 15 were white (75%). The mean
age was 50 years (range: 20 to 70 years). Figure 2 shows
boxplots of the perfusion measures (A and B) and the
three survey scores (C, D, and E). Tables 2 and 3 show
the ‘within group’ changes seen in the repeated measure
analyses of variance models.
Under normal conditions (Table 2), overall, there was a
0.11 pU increase in perfusion in the ambrisentan group as
compared to 0.18 pU increase in the placebo group from
baseline to week 1 (P = 0.41); there was a 0.01 pU decrease
in the ambrisentan group as compared to 0.06 pU de-
crease in the placebo group from baseline to week 12 (P =
0.93). There was a 0.12 pU decrease in the ambrisentan
group versus 0.24 pU decrease in the placebo group from
week 1 to week 12 (P = 0.37). Under normal conditions,
no significant differences were noted overall (P = 0.61), or
specifically in the areas of worst perfusion (P = 0.25).
Under cold conditions (10°C for two minutes), there
was a 0.07 pU increase in the overall flow in the ambrisen-
tan group as compared to 0.13 pU decrease in the placebo
group from baseline to week 1 (P = 0.52) (Table 3); a 0.08
pU decrease in the overall flow in the ambrisentan group
versus 0.17 pU decrease in the placebo group from base-
line to week 12 (P = 0.46), and a 0.15 pU decrease in the
overall flow in the ambrisentan group versus 0.04 pU de-
crease in the placebo group from week 1 to week 12 (P =
0.17). No significant differences were noted under cold
conditions (P = 0.39). While no significant changes in the
areas of worst perfusion were noted between the two
groups from baseline to week 12 (P = 0.46), on cold chal-
lenge, there were significant decreases in perfusion in the
ambrisentan group from week 1 to week 12 in R1 (P =
0.015) and the regions of worst perfusion (P = 0.012).
Table 4 shows the changes in survey responses within
each group. Significant improvements in the S-HAQ scores
and RCS were seen in the ambrisentan group at week 1
and week 12 relative to baseline, implying better quality of
life and less Raynaud attacks. For the S-HAQ scores, there
was a 0.12 point decrease (improvement) in the ambrisen-
tan group versus 0.13 in the placebo group from baseline to
week 1, 0.20 point decrease in both groups from baseline to
week 12, and a 0.09 point decrease in the ambrisentan
group versus 0.08 in the placebo group from week 1 to
week 12; overall, there was a significant improvement in
the S-HAQ scores over time (P = 0.005). On the RCS, there
Table 1 Summary of the demographic characteristics of the cohort
Total Ambrisentan Placebo
Factor Level Number Number (%) Number (%)
Gender
Female 16 13 86.7 3 60.0
Male 4 2 13.3 2 40.0
Age
Mean (SD) 20 15 50.6 (12.8) 5 46.8 (10.5)
Race
Non-White 5 4 26.7 1 20.0
White 15 11 73.3 4 80.0
Ethnicity
Non-Hispanic 20 15 100.0 5 100.0
Smoking
No 20 15 100.0 5 100.0
Scleroderma
Limited 20 15 100.0 5 100.0
SD = standard deviation.
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0.20 point decrease in the placebo group from baseline to
week 1, but then a 1.46 point decrease in the ambrisentan
group versus a 0.20 point decrease in the placebo group
from baseline to week 12, and a 1.66 point decrease in the
ambrisentan group versus no change in the placebo group
from week 1 to week 12. We did observe a statistically sig-
nificant improvement in the RCS over time (P = 0.001).
For the P-VAS scores, there was a 0.47 point decrease (im-
provement) in the ambrisentan group versus a 0.20 point
increase (worsening) in the placebo group from baseline
to week 1, a 0.66 point decrease in the ambrisentan group
versus 0.80 decrease in the placebo group from baseline to
week 12, and a 0.20 point decrease in the ambrisentan
group as compared to 1.00 decrease in the placebo group
from week 1 to week 12 (P = 0.14). Therefore, there was
no significant change overall in the P-VAS scores. All pa-
tients completed the first two visits. One patient did not
complete the third visit and another stopped the study
medication after four weeks but subsequently completed
the 12 week visit. Both these subjects were in the ambri-
sentan group (Figure 1).
Adverse events
One patient in the placebo group had a drop in hemoglobin
from 11 g/dl to 10 g/dl at one month which returned to 11
g/dl on repeat testing. Another patient was hospitalized for
viral pneumonia.
Discussion
This is the first randomized, double-blind, placebo-
controlled study investigating the effect of an ETAreceptor antagonist on digital microvascular flow in lim-
ited SSc. The purpose of choosing ambrisentan, a select-
ive ETA antagonist (as opposed to bosentan, a dual ETA
and ETB antagonist) was its ability to permit the vaso-
dilator effect of endothelin through its interaction with the
ETB receptor, while inhibiting its vasoconstrictive effect
through its interaction with the ETA receptor. Although
the practical implications and advantages (if any) of this
selective inhibition are not clear at this time, it was specu-
lated that maintaining the vasodilator effect of endothelin
by unimpeded ETB receptor stimulation might have an ad-
vantage over bosentan in augmenting digital microvascu-
lar flow in SSc patients.
Our results indicated no improvement at week 1 in
the mean microvascular blood flow compared to pla-
cebo, indicating no demonstrable vasodilatory effect of
ambrisentan. Also, at week 12, the differences in mean
blood flow did not reach statistical significance, indicating
no significant anti-fibro-proliferative effect of ambrisentan
either, in the given time frame of three months. We did
observe a significant improvement in the S-HAQ score
(P = 0.005) and the RCS (P = 0.001), with no detectable
change in the P-VAS score (P = 0.14).
The possibility of inter-observer differences was elimi-
nated by having the same investigator (NB) consistently
mark the ROIs for each patient and comparing to corre-
sponding images from previous visits. Patients were peri-
odically counseled to ensure medication compliance.
Based on data derived from our preliminary study
[11], we defined a minimal clinically important differ-
ence (MCID) between the two arms. A small sample size
is unlikely to be the primary cause of non-significance in
Figure 2 Boxplots showing perfusion measures at normal temperature and during cold challenge, S-HAQ scores, RCS and P-VAS
scores. (A) Boxplots showing perfusion measures at baseline, week 1 and week 12 at normal temperature. Black boxes represent ambrisentan
and gray boxes represent placebo. The bottom and top of the boxes represent the 25th and 75th percentiles, respectively; the band within the
box is the median, and the ends of the whiskers are the minimum and maximum of all the data in that group; the square within the box is the
mean. The dots on the left of each boxplot represent perfusion measures from individual subjects. (B) Boxplots showing perfusion measures at
baseline, week 1 and week 12 during cold challenge. (C) Boxplots showing S-HAQ scores at baseline, week 1 and week 12. (D) Boxplots showing
RCS at baseline, week 1 and week 12. (E) Boxplots showing P-VAS scores at baseline, week 1 and week 12. P-VAS, Pain-Visual Analog Score; RCS,
Raynaud Condition Scale; s-HAQ, Scloderma-Health Assessment Questionnaire.
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in some regions over time. If these trends remained, it is
unlikely that an increase in sample size would have led
to a change in the conclusion that ambrisentan fails to
induce clinically meaningful improvement in perfusion.
Therefore, we conclude that a three-month course of
ambrisentan is ineffective in improving digital micro-
vascular flow in patients with limited SSc.
In a recent open label study, bosentan was used in SSc
patients with PAH along with nifedipine [17]. Although
digital blood flow improved, symptoms of RP were notdecreased. Moreover, it was difficult to assess the relative
contribution of bosentan on digital blood flow, as the
patients also received nifedipine.
Under physiologic conditions, cutaneous blood flow is
extremely variable and may be affected by a number of
intrinsic and extrinsic factors that vary over time, for
example, systemic blood pressure, body temperature,
ambient temperature, stress level, hemoglobin level,
food intake, smoking status, medications, and so on.
Many other unidentified factors are also probably in-
volved in cutaneous vasoregulation. Digital blood flow
Table 2 Summary of changes of all region perfusion responses by treatment and time under normal conditions
Placebo Ambrisentan
Measure Change period Change (95% CI) Change P-value Overall P-value Change (95% CI) Change P-value Overall P-value
All 1 W - Base 0.18 (−0.27,0.63) 0.42 0.54 0.11 (−0.15,0.37) 0.41 0.61
12 W - Base −0.06 (−0.51,0.39) 0.80 −0.01 (−0.28,0.25) 0.93
12 W - 1 W −0.24 (−0.69,0.21) 0.29 −0.12 (−0.38,0.15) 0.37
R1 1 W - Base 0.23 (−0.18,0.64) 0.26 0.29 0.12 (−0.11,0.36) 0.29 0.30
12 W - Base −0.08 (−0.48,0.33) 0.71 −0.06 (−0.30,0.18) 0.62
12 W - 1 W −0.31 (−0.71,0.10) 0.14 −0.18 (−0.42,0.06) 0.13
R2 1 W - Base 0.15 (−0.32,0.62) 0.52 0.76 0.03 (−0.24,0.31) 0.80 0.80
12 W - Base 0.00 (−0.47,0.47) 0.99 −0.06 (−0.34,0.22) 0.68
12 W - 1 W −0.15 (−0.62,0.32) 0.53 −0.09 (−0.37,0.19) 0.51
R3 1 W - Base 0.08 (−0.42,0.57) 0.76 0.79 0.12 (−0.17,0.40) 0.40 0.70
12 W - Base −0.09 (−0.59,0.40) 0.71 0.05 (−0.24,0.34) 0.71
12 W - 1 W −0.17 (−0.66,0.33) 0.50 −0.07 (−0.36,0.23) 0.65
R4 1 W - Base 0.27 (−0.26,0.80) 0.31 0.42 0.15 (−0.16,0.45) 0.33 0.57
12 W - Base −0.06 (−0.59,0.47) 0.81 0.02 (−0.30,0.33) 0.91
12 W - 1 W −0.33 (−0.86,0.20) 0.22 −0.13 (−0.45,0.18) 0.40
Worst 1 W - Base 0.18 (−0.20,0.56) 0.35 0.45 0.18 (−0.04,0.40) 0.10 0.25
12 W - Base −0.05 (−0.43,0.33) 0.79 0.06 (−0.16,0.29) 0.57
12 W - 1 W −0.23 (−0.61,0.15) 0.23 −0.12 (−0.34,0.11) 0.29
The ROIs are mentioned as R1 to R4 along with the area of worst perfusion, measured over the study duration. P-values are from repeated measure analysis of
variance models. Base = baseline; W = week; Worst = worst perfusion. CI, confidence interval; ROI, region of interest.
Table 3 Summary of changes of all region perfusion responses by treatment and time under cold conditions
Placebo Ambrisentan
Measure Change period Change (95% CI) Change P-value Overall P-value Change (95% CI) Change P-value Overall P-value
All 1 W - Base −0.13 (−0.50,0.24) 0.47 0.62 0.07 (−0.15,0.28) 0.52 0.39
12 W - Base −0.17 (−0.54,0.20) 0.35 −0.08 (−0.30,0.14) 0.46
12 W - 1 W −0.04 (−0.41,0.33) 0.82 −0.15 (−0.37,0.07) 0.17
R1 1 W - Base −0.07 (−0.40,0.25) 0.65 0.65 0.19 (−0.00,0.38) 0.054 0.036
12 W - Base −0.15 (−0.48,0.18) 0.35 −0.06 (−0.25,0.13) 0.54
12 W - 1 W −0.08 (−0.41,0.25) 0.64 −0.25 (−0.44,-0.05) 0.015
R2 1 W - Base −0.05 (−0.45,0.36) 0.81 0.79 0.07 (−0.17,0.30) 0.56 0.33
12 W - Base −0.13 (−0.54,0.27) 0.51 −0.11 (−0.35,0.13) 0.36
12 W - 1 W −0.09 (−0.49,0.32) 0.67 −0.18 (−0.42,0.06) 0.14
R3 1 W - Base −0.19 (−0.59,0.21) 0.35 0.54 0.07 (−0.16,0.30) 0.54 0.44
12 W - Base −0.19 (−0.59,0.21) 0.33 −0.08 (−0.32,0.16) 0.50
12 W - 1 W −0.01 (−0.41,0.39) 0.98 −0.15 (−0.39,0.09) 0.21
R4 1 W - Base −0.22 (−0.69,0.25) 0.36 0.57 −0.05 (−0.32,0.22) 0.70 0.84
12 W - Base −0.21 (−0.69,0.26) 0.37 −0.08 (−0.36,0.20) 0.57
12 W - 1 W 0.01 (−0.47,0.48) 0.98 −0.03 (−0.31,0.25) 0.84
Worst 1 W - Base −0.11 (−0.43,0.20) 0.47 0.41 0.18 (−0.01,0.36) 0.058 0.031
12 W - Base −0.21 (−0.53,0.11) 0.19 −0.07 (−0.26,0.12) 0.46
12 W - 1 W −0.10 (−0.41,0.22) 0.54 −0.25 (−0.43,-0.06) 0.012
The ROIs are mentioned as R1 to R4 along with the area of worst perfusion, measured over the study duration. P-values are from repeated measure analysis of
variance models. Base = baseline; W = week; Worst = worst perfusion. CI, confidence interval; ROI, region of interest.
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Table 4 Summary of changes in all survey responses by treatment and time
Placebo Ambrisentan
Measure Change period Change (95% CI) Change P-value Overall P-value Change (95% CI) Change P-value Overall P-value
S-HAQ 1 W - Base −0.13 (−0.33,0.08) 0.22 0.14 −0.12 (−0.23,-0.00) 0.048 0.005
12 W - Base −0.20 (−0.40,0.00) 0.051 −0.20 (−0.32,-0.08) 0.001
12 W - 1 W −0.08 (−0.28,0.13) 0.45 −0.09 (−0.21,0.03) 0.15
RCS 1 W - Base −0.20 (−1.74,1.34) 0.79 0.95 0.20 (−0.69,1.09) 0.65 0.001
12 W - Base −0.20 (−1.74,1.34) 0.79 −1.46 (−2.37,-0.55) 0.002
12 W - 1 W −0.00 (−1.54,1.54) 0.99 −1.66 (−2.57,-0.75) <0.001
P-VAS 1 W - Base 0.20 (−0.95,1.35) 0.73 0.19 −0.47 (−1.13,0.20) 0.16 0.14
12 W - Base −0.80 (−1.95,0.35) 0.17 −0.66 (−1.35,0.02) 0.056
12 W - 1 W −1.00 (−2.15,0.15) 0.087 −0.20 (−0.88,0.49) 0.56
P-values are from repeated measure analysis of variance models. Base = baseline; W = week; CI, confidence interval; P-VAS, Visual Analog Scale for Pain; RCS,
Raynaud’s Condition Score; S-HAQ, Scleroderma Health Assessment Questionnaire.
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these variables, accurate evaluation of digital microvascu-
lar flow is difficult. Consequently, a clinically meaningful
appraisal of the effect of vasoactive therapy on digital
blood flow is extremely challenging.
In addition to the physiological variability discussed
above, scleroderma patients have some additional chal-
lenges that affect reliable interpretation of LDPI mea-
surements. Mapping the ROIs is difficult in some SSc
patients because of contractures in their hands and fin-
gers. Moreover, the depth of penetration of the laser
beam could vary according to the degree of skin thick-
ening at the ROIs. Seventy-five percent of our patients
were white and the rest were non-white; this may also
be relevant, as the melanin content in the skin can
influence the passage of laser beams and perfusion
measures. Furthermore, as progressive microvascular
fibrosis and small blood vessel rarefaction is known to
occur over time, the duration of SSc diagnosis may
affect digital blood flow. Although, it is assumed that
the variables that affect digital blood flow should
equally affect ambrisentan and placebo arms, variabil-
ity due to chance cannot be excluded with small
sample sizes. Nevertheless, in spite of all of the limita-
tions mentioned above, we used LDPI in our study, as
it has several advantages over most other existing
methods in objectively assessing digital microvascular
flow, and has hence become an established technology
in the assessment of digital micro-circulation in
scleroderma [10-18].
The results of our study indicate that ambrisentan, an
ETA receptor antagonist, does not significantly impact
digital microvascular flow in SSc patients. Although
digital arterioles are similar to pulmonary arterioles
both structurally and in size, there may be unknown
differences that could possibly explain this differential
vaso-modulator response to ambrisentan, includingcertain intrinsic variations in the blood vessels that are
presently unknown, or differences in the local micro-
milieu. Thus, ACE-inhibitors are effective and life-
saving in an SSc renal crisis, establishing an important
role of the renin-angiotensin system in the renal micro-
vasculopathy in SSc; yet, these agents are ineffective in
the treatment of SSc associated RP [29].
It has been suggested by prior studies that although
bosentan may be effective in preventing ischemic digital
ulcers, it does not alleviate SSc-associated RP and hand
pain [2,9]. This may indicate that digital blood flow and
ischemic digital ulceration and necrosis are possibly me-
diated by overlapping but not necessarily congruent
pathways or mediators; conceivably, both of these path-
ways are dysregulated in SSc, the latter being partially
controlled by endothelin, but not necessarily the former.
Possibly other potential mediators of microvascular flow
such as catecholamines, angiotensin II, prostanoids, and
nitric oxide may play a more prominent role than
endothelin in the regulation of digital microcirculation
in SSc.
The discrepancy between the lack of improvement in
blood flow and improvement in the RCS and S-HAQ
scores remains unexplained, but suggests that these sub-
jective measures of symptomatic improvement of Ray-
naud phenomena and of functional status may not be
entirely mediated through reversal of digital ischemia,
but possibly through other factors, such as improvement
in hand function and overall quality of life. This decoup-
ling might be perceived to hint at some off target effects
of ambrisentan not involving vasodilatory or anti-
proliferative pathways.Conclusions
Continuous use of ambrisentan for three months did not
demonstrate any evidence of improvement of digital
Bose et al. Arthritis Research & Therapy  (2015) 17:44 Page 9 of 10microperfusion in limited SSc patients although patient
oriented outcomes were quite favorable. Larger, pro-
spective trials are needed to validate our results.
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